| Q35029533 | Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors |
| Q36956837 | Breast cancer survivorship symptom management: current perspective and future development |
| Q37588174 | Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer |
| Q37373590 | Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial |
| Q35687686 | Joint symptoms, aromatase inhibitor-related adverse reactions, are indirectly associated with decreased serum estradiol |
| Q35233959 | Online discussion of drug side effects and discontinuation among breast cancer survivors |
| Q90270469 | Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors |
| Q36692645 | Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors |
| Q35215032 | Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors |
| Q34045510 | The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia |
| Q26824711 | Vitamin D and breast cancer: interpreting current evidence |
| Q33885643 | Vitamin d in the prevention of aromatase inhibitor-induced musculoskeletal symptoms: is it ready for practice? |
| Q36692336 | Vitamin d: are we ready to supplement for breast cancer prevention and treatment? |